Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Sentinel Diagnostics

Sentinel Diagnostics develops and manufactures in-vitro diagnostic medical devices for routine analysis and specific ... read more Featured Products: More products

Download Mobile App





Sentinel Group Presents Full Diagnostic Portfolio at MEDICA 2025

By LabMedica International staff writers
Posted on 18 Nov 2025

The Sentinel Group, comprised of Setinel Diagnostics, Eureka Lab Division, and PRIMA Lab, is taking part in MEDICA 2025. More...

At booth D16 in Hall 3, Sentinel is showcasing solutions spanning fecal immunochemical testing, molecular diagnostics, chromatography, and lateral‑flow rapid tests.

Molecular diagnostic solutions on display from Sentinel Diagnostics include the SENTiNAT 200, a fully automated platform that provides everything required to perform complete multiparametric real-time PCR analyses for pathogen detection and quantification in human samples. The system is designed to work with STAT-NAT lyophilized kits (Stabilized Amplification Technology), based on Sentinel’s patented formulation developed to ensure long-term assay stability at room temperature.

Sentinel Diagnostics is also highlighting its complete line for fecal immunochemical testing (FIT) at MEDICA 2025. This includes the FOB Gold system, which features a unique “2-in-1” sample collection tube and a next-generation immunological latex reagent for detecting fecal occult blood. Additionally, the company is presenting CALiaGold, a quantitative latex immunoassay for fecal calprotectin measurement, a key marker of intestinal inflammation. Used together with the automated SENTiFIT 270 and SENTiFOB analyzers, CALiaGold provides a diagnostic workflow that helps differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS).

The company is further showcasing the SENTiFIT 8000, a high-throughput system for fecal immunochemistry designed for colorectal cancer (CRC) screening programs and laboratories handling large volumes of fecal samples. For fully automated sample loading, the analyzer connects to the RH-150 Rack Handler or can be integrated into a Total Laboratory Automation (TLA) system, enhancing efficiency and reducing manual workload.

At the Sentinel Group booth, PRIMA Lab is exhibiting its range of point-of-care rapid tests, including self-tests for Strep A and HIV 1/2, as well as rapid tests for C-reactive protein, urinary tract infections, vaginal pH, gastrointestinal pathogens, celiac disease, and fecal occult blood.

Eureka Lab Division, also part of the Sentinel Group, is presenting the world’s largest range of ready-to-use diagnostic kits for chromatographic analytical instruments. The company provides solutions that simplify, standardize, and improve analytical procedures in clinical laboratories through ready-to-use kits compatible with HPLC, GC, GC-MS, and LC-MS/MS techniques.

The Sentinel Group’s participation in MEDICA 2025 is described as a key moment to strengthen the group’s international presence and reaffirm its role as a strategic partner for laboratories, hospitals, research centers, and healthcare institutions worldwide.

Related Links:
Sentinel Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Immunofluorescence Analyzer
IFA System
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.